Skip to main content
. 2023 Mar 16;37(5):1068–1079. doi: 10.1038/s41375-023-01867-3

Fig. 6. Combined ERK1/2 and JAK1/2 inhibition reduces plasma OPN and reverses BM fibrosis induced by Romiplostim.

Fig. 6

A OPN plasma concentration was evaluated by means of ELISA (enzyme-linked immunosorbent assay) in control mice (Untreated) and Romiplostim-treated animals receiving vehicle (Rom + Vehicle, in blue), Ulixertinib (Rom + Ulix, in green), Ruxolitinib (Rom + Ruxo, in red) or a combination of Ulixertinib and Ruxolitinib (Rom + Ruxo + Ulix, in purple). ELISA was performed 11 days after the first Romiplostim administration (n = 7–9/group). Histograms represent mean values while bars indicate the standard deviation. Comparisons were performed by means of one-way ANOVA. B Blinded fibrosis grade quantification was performed by a specialized pathologist (n = 4–8/group) Histograms represent median values while bars indicate the interquartile range. Comparisons were performed by means of Kruskal-Wallis’ test. C Representative images of Gordon and Sweet’s reticulin staining of BM sections from mice belonging to each experimental group. Magnification 200×. D Spleen fibrosis as shown by Gordon and Sweet’s reticulin staining. Magnification 200X. *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001; ****: P ≤ 0.0001 Abbreviations: OPN osteopontin; Rom romiplostim; Ulix Ulixertinib; Ruxo Ruxolitinib; BM bone marrow.